JAK Inhibitor (Janus Kinase Inhibitor)

JAK Inhibitor refers to small-molecule drugs that block Janus kinase enzymes involved in cytokine receptor signalling, reducing inflammatory and immune activation pathways. These inhibitors interfere with JAK-STAT signalling cascades, decreasing transcription of pro-inflammatory genes and modulating immune cell function. JAK inhibitors are used across autoimmune and inflammatory diseases, offering oral alternatives to biologic therapies in certain indications.

The biopharmaceutical industry develops JAK inhibitors for conditions including rheumatoid arthritis, ulcerative colitis, atopic dermatitis, and other immune-mediated disorders. Drug development focuses on selectivity across JAK1, JAK2, JAK3, and TYK2 to balance efficacy with safety. Clinical programmes monitor adverse effects including infections, thrombosis risk, and laboratory abnormalities such as lipid changes. Regulatory pathways require robust long-term safety data due to broad immune pathway modulation. As immunology pipelines expand, JAK inhibitors remain a major therapeutic class with ongoing innovation in selectivity and risk management, including next-generation selective inhibitors aiming to improve the therapeutic index.